1. Heidari B. Rheumatoid arthritis: early diagnosis and treatment outcomes. Caspian Jounal of Internal Medicine. 2011;2(1):161-70.
2. Miedany YE, Youssef S, Mehanna A, Gaafary ME. Development of a scoring system for assessment of outcome of early undifferentiated inflammatory synovitis. Joint Bone Spine. 2008;75(2):155-62.
3. Birch J, Bhattacharya S. Emerging trends in diagnosis and treatment of rheumatoid arthritis. Primary Care: Clinics in Office Practice. 2010;37(4):779-92.
4. Nikiphorou E, de Lusignan S, Mallen CD, Khavandi K, Bedarida G, Buckley CD, et al. Cardiovascular risk factors and outcomes in early rheumatoid arthritis: a population-based study. Heart. 2020;106(20):1566-72.
5. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580-8.
6. Durand C, Eldoma M, Marshall DA, Bansback N, Hazlewood GS. Patient preferences for disease modifying anti-rheumatic drug treatment in rheumatoid arthritis: A systematic review. The Journal of rheumatology. 2019:jrheum.181165.
7. Gerlag D, Raza K, Baarsen Lv, al e. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Annals of the Rheumatic Diseases. 2012;71(5):638-41.
8. Niemantsverdriet E, Dakkak YJ, Burgers LE, Bonte-Mineur F, Steup-Beekman GM, van der Kooij SM, et al. TREAT Early Arthralgia to Reverse or Limit Impending Exacerbation to Rheumatoid arthritis (TREAT EARLIER): a randomized, double-blind, placebo-controlled clinical trial protocol. Trials. 2020;21(1):862.
9. van Boheemen L, ter Wee M, Turk S, van Beers M, Bos W, Marsman D, et al. The STAtins to Prevent Rheumatoid Arthritis (STAPRA) Trial: Clinical Results and Subsequent Qualitative Study, a Mixed Method Evaluation Arthritis Rheumatol 2020;72
10. Gerlag D, Safy M, Maijer K, al e. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. Annals of the Rheumatic Diseases. 2019;78(2):179-85.
11. Bos W, Dijkmans B, Boers M, Stadt Rvd, Schaardenburg Dv. Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial. Annals of the Rheumatic Diseases. 2010;69(3):571-4.
12. Al-Laith M, Jasenecova M, Abraham S, Bosworth A, Bruce IN, Buckley CD, et al. Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. Trials. 2019;20(1):429-.
13. RTCure: Rheuma Tolerance for Cure 2020 [Available from: https://www.rtcure.com/.
14. Falahee M, Finckh A, Raza K, Harrison M. Preferences of Patients and At-risk Individuals for Preventive Approaches to Rheumatoid Arthritis. Clin Ther. 2019;41(7):1346-54.
15. Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. American Journal of Managed Care. 2012;18:295-302.
16. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-9, w64.
17. Empire Rheumatism Council : Multi-Centre Controlled Trial of Cortisone Acetate and Acetyl Salicylic Acid in the Long-Term Treatment of Rheumatoid Arthritis † Results of Three Years' Treatment. Annals of the Rheumatic Diseases. 1957;16(3):277-89.
18. Joy SM, Little E, Maruthur NM, Purnell TS, Bridges JF. Patient preferences for the treatment of type 2 diabetes: a scoping review. Pharmacoeconomics. 2013;31(10):877-92.
19. Fraenkel L, Cunningham M, Peters E. Subjective numeracy and preference to stay with the status quo. Med Decis Making. 2015;35(1):6-11.
20. Fraenkel L, Bogardus ST, Concato J, Felson DT, Wittink DR. Patient preferences for treatment of rheumatoid arthritis. Ann Rheum Dis. 2004;63(11):1372-8.
21. Constantinescu F, Goucher S, Weinstein A, Fraenkel L. Racial disparities in treatment preferences for rheumatoid arthritis. Med Care. 2009;47(3):350-5.
22. Constantinescu F, Goucher S, Weinstein A, Smith W, Fraenkel L. Understanding why rheumatoid arthritis patient treatment preferences differ by race. Arthritis Rheum. 2009;61(4):413-8.
23. Scalone L, Sarzi-Puttini P, Sinigaglia L, Montecucco C, Giacomelli R, Lapadula G, et al. Patients', physicians', nurses', and pharmacists' preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases. Patient Prefer Adherence. 2018;12:2153-68.
24. Alten R, Kruger K, Rellecke J, Schiffner-Rohe J, Behmer O, Schiffhorst G, et al. Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach. Patient Prefer Adherence. 2016;10:2217-28.
25. Fraenkel L, Nowell WB, Michel G, Wiedmeyer C. Preference phenotypes to facilitate shared decision-making in rheumatoid arthritis. Ann Rheum Dis. 2018;77(5):678-83.
26. Bansback N, Harrison M, Marra C. Does Introducing Imprecision around Probabilities for Benefit and Harm Influence the Way People Value Treatments? Med Decis Making. 2016;36(4):490-502.
27. Harrison M, Marra C, Shojania K, Bansback N. Societal preferences for rheumatoid arthritis treatments: evidence from a discrete choice experiment. Rheumatology (Oxford). 2015;54(10):1816-25.
28. Díaz-Torné C, Urruticoechea-Arana A, Ivorra-Cortés J, Díaz S, Dilla T, Sacristán JA, et al. What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis. Advances in Therapy. 2020;37(4):1479-95.
29. Hazlewood GS, Bombardier C, Tomlinson G, Marshall D. A Bayesian model that jointly considers comparative effectiveness research and patients' preferences may help inform GRADE recommendations: an application to rheumatoid arthritis treatment recommendations. J Clin Epidemiol. 2018;93:56-65.
30. Hazlewood GS, Bombardier C, Tomlinson G, Thorne C, Bykerk VP, Thompson A, et al. Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment. Rheumatology (Oxford). 2016;55(11):1959-68.
31. Husni ME, Betts KA, Griffith J, Song Y, Ganguli A. Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective. Rheumatol Int. 2017;37(9):1423-34.
32. Nolla JM, Rodriguez M, Martin-Mola E, Raya E, Ibero I, Nocea G, et al. Patients' and rheumatologists' preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain. Patient Prefer Adherence. 2016;10:1101-13.
33. Ozdemir S, Johnson FR, Hauber AB. Hypothetical bias, cheap talk, and stated willingness to pay for health care. J Health Econ. 2009;28(4):894-901.
34. Skjoldborg US, Lauridsen J, Junker P. Reliability of the discrete choice experiment at the input and output level in patients with rheumatoid arthritis. Value Health. 2009;12(1):153-8.
35. Finckh A, Escher M, Liang MH, Bansback N. Preventive Treatments for Rheumatoid Arthritis: Issues Regarding Patient Preferences. Current Rheumatology Reports. 2016;18(8):51.
36. Harrison M, Bansback N, Aguiar M, Koehn C, Shojania K, Finckh A, et al. Preferences for treatments to prevent rheumatoid arthritis in Canada and the influence of shared decision-making. Clinical Rheumatology. 2020.
37. Harrison M, Spooner L, Bansback N, Milbers K, Koehn C, Shojania K, et al. Preventing rheumatoid arthritis: Preferences for and predicted uptake of preventive treatments among high risk individuals. PLoS One. 2019;14(4):e0216075-e.
38. Munro S, Spooner L, Milbers K, Hudson M, Koehn C, Harrison M. Perspectives of patients, first-degree relatives and rheumatologists on preventive treatments for rheumatoid arthritis: a qualitative analysis. BMC Rheumatology. 2018;2(1):18.
39. Veldwijk J, Groothuis-Oudshoorn C, Kihlbom U, Langenskiöld S, Dekker E, Kallenberg F, et al. How psychological distance of a study sample in discrete choice experiments affects preference measurement: a colorectal cancer screening case study. . Patient Prefer Adherence 2019;13:273-82.
40. Russo S, Jongerius C, Faccio F, Pizzoli SFM, Pinto CA, Veldwijk J, et al. Understanding Patients' Preferences: A Systematic Review of Psychological Instruments Used in Patients' Preference and Decision Studies. Value Health. 2019;22(4):491-501.
41. Bywall KS, Kihlbom U, Hansson M, Falahee M, Raza K, Baecklund E, et al. Patient preferences on rheumatoid arthritis second-line treatment: a discrete choice experiment of Swedish patients. Arthritis Res Ther. 2020;22(1):288.
42. Simons G, Belcher J, Morton C, Kumar K, Falahee M, Mallen CD, et al. Symptom Recognition and Perceived Urgency of Help-Seeking for Rheumatoid Arthritis and Other Diseases in the General Public: A Mixed Method Approach. Arthritis Care & Research. 2017;69(5):633-41.
43. Simons G, Mallen CD, Kumar K, Stack RJ, Raza K. A Qualitative Investigation of the Barriers to Help-seeking Among Members of the Public Presented with Symptoms of New-onset Rheumatoid Arthritis. The Journal of Rheumatology. 2015;42(4):585-92.
44. Cornelis F, finkh A. AB0225 Recruitment difficulty for unaffected rheumatoid arthritis relatives due to misplaced guilt ? Ann Rheum Dis. 2013;72(Suppl 3):A855-A6.
45. Vass CM, Payne K. Using Discrete Choice Experiments to Inform the Benefit-Risk Assessment of Medicines: Are We Ready Yet? PharmacoEconomics. 2017;35(9):859-66.
46. van Steenbergen HW, Aletaha D, Beaart-van de Voorde LJ, Brouwer E, Codreanu C, Combe B, et al. EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. Ann Rheum Dis. 2017;76(3):491-6.
47. Deane KD, Holers VM. Rheumatoid Arthritis Pathogenesis, Prediction, and Prevention: An Emerging Paradigm Shift. Arthritis & Rheumatology.n/a(n/a).
48. Augustovski F, Beratarrechea A, Irazola V, Rubinstein F, Tesolin P, Gonzalez J, et al. Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment. Value Health. 2013;16(2):385-93.
49. Louder AM, Singh A, Saverno K, Cappelleri JC, Aten AJ, Koenig AS, et al. Patient Preferences Regarding Rheumatoid Arthritis Therapies: A Conjoint Analysis. Am. 2016;9(2):84-93.
50. Poulos C, Hauber AB, Gonzalez JM, Turpcu A. Patients' willingness to trade off between the duration and frequency of rheumatoid arthritis treatments. Arthritis Care Res (Hoboken). 2014;66(7):1008-15.